|
NATHEALTH and APACMED join hands to
advance medical technology for UHC in India
In India, the government schemes such as Pradhan
Mantri Swasthya Suraksha Yojana (PMSSY) and Ayushman Bharat-Pradhan Mantri Jan
Arogya Yojana have helped India take bold steps towards UHC.
New Delhi, September 9, 2020: India is committed to
meeting UNSDGs and SDG 3 is a critical goal, that impact all others. Further,
advancing medical technology is pivotal to achieving Universal Health Coverage (UHC)
in India. In keeping with the above, the industry body, NATHEALTH - Healthcare
Federation of India, renowned as the credible voice of the health sector of
India and the Asia Pacific Medical Technology Association (APACMed), the
regional association of medical technology in the Asia Pacific today signed a
Memorandum of Understanding (MoU) to harness the role of the medical technology
industry in India, in relation to AB-PMJAY and to ensure that it optimally
engages with relevant policymakers, helping shape polices leading to achieving
UHC in India.
The goal of this strategic partnership is to enable
a seamless pathway that streamlines all innovations ensuring that it scales and
increases the concerted efforts by both organizations. Both NATHEALTH and
APACMed would work through a joint working group in formulating a work plan in
relation to Universal Healthcare in India, that would synergize and complement
the efforts of the government to maximize patient health outcomes through
quality care relative to expenditures.
Speaking about the partnership, Ms. Preetha Reddy,
President – NATHEALTH & Vice Chairperson, Apollo Hospitals said, “The COVID-19
pandemic has been highlighting the fault lines even in the most advanced nations
and underlined the acute need for a robust mechanism for UHC.
In India, the government schemes such as Pradhan
Mantri Swasthya Suraksha Yojana (PMSSY) and Ayushman Bharat-Pradhan Mantri Jan
Arogya Yojana have helped India take bold steps towards UHC. Now going forward,
it is vital that there are strong collaborative efforts by the government and
private health sector organizations, which will be the key to digitally
transform the Indian healthcare system. The MoU and partnership between
NATHEALTH and APACMeD will work to increase access to innovative medical
technologies, that which will lead to high quality and affordable healthcare
delivery and complement the efforts of the Government’s UHC agenda.
https://health.economictimes.indiatimes.com/news/medical-devices/nathealth-and-apacmed-join-hands-to-advance-medical-technology-for-uhc-in-india/78029922
Kraton’s BIAXAM kills up to
99.99% of microbes including SARS-CoV-2
Kraton Corporation, a leading global producer of specialty polymers and
high-value bio-based products, is seeking regulatory approval for BIAXAM, a
novel sulfonated polymer technology with long-lasting self-disinfecting
properties that has been demonstrated in studies to quickly inactivate up to
99.99% of SARS-CoV-2 (virus that causes COVID-19) and other microbes. Kraton
developed the BIAXAM technology as part of its sulfonated polymer product line
and plans to expand product testing and seek regulatory approval for use as a
durable, long-lasting disinfectant from the United States Environmental
Protection Agency (EPA).
The efficacy of Kraton's BIAXAM technology has been
thoroughly studied by renowned organizations. The testing performed at the UTMB
and Boston University BSL-4 laboratories has demonstrated BIAXAM to be effective
against SARS-CoV-2 and other microbes.
Depending on the regulatory approval process or
certification requirements by country, Kraton believes that BIAXAM could be used
as a coating on PPE and a variety of high-contact surfaces. Additionally, it
could be used as a replaceable peel-and-stick film for a broad range of
applications including medical, textiles, building and construction, and
packaging.
SVP and CTO Dr Vijay Mhetar said: "BIAXAM offers
rapid and long-lasting performance, unlike current disinfectant offerings that
are only effective immediately or require periodic treatment or re-application.
Currently there are no EPA-approved long-lasting disinfectants, so this
technology is truly extraordinary. We believe the EPA would approve BIAXAM for
the US market and allow us to market the solution due to the novel
anti-microbial properties it has demonstrated."
The BIAXAM technology is patent-pending and will be
commercially available shortly. For the US market, until EPA approval is
obtained, BIAXAM cannot be sold, marketed or distributed as components of
products that kill or repel or claim to kill or repel microbes such as virus,
bacteria or mold.
President and CEO Kevin M. Fogarty added: "We've
been developing this technology for some time for other applications, but the
recent pandemic has led to an urgent and high demand for anti-microbial
materials. We are excited about the possibility of bringing this innovation to
market. We are currently conducting discussions with a number of possible
development partners to explore potential applications."
https://www.medicalplasticsnews.com/mpn-north-america/kraton%E2%80%99s-biaxam-kills-up-to-99-99-of-microbes-including-sars/
|
